Sees Q4 adjusted EBITDA of $0.3M-$2.3M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst Reports Third Quarter 2023 Results
- Health Catalyst Acquires ERS, Bolsters Tech-Enabled Managed Services Offering with Data Abstraction and Oncology Registry Management Capabilities
- Health Catalyst price target lowered to $8 from $13 at RBC Capital
- Health Catalyst sees 2023 revenue $291M-$296M, consensus $293.78M
- Health Catalyst sees Q4 revenue $70.1M-$75.1M, consensus $73.96M